Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)
CONCLUSIONS
Faster aspart effectively improved HbA1c, and noninferiority to IAsp was confirmed, with superior PPG control for mealtime faster aspart versus IAsp. Subjects randomized to postmeal faster aspart for all meals maintained HbA1c noninferior to that obtained with mealtime IAsp. (Source: Diabetes Care)
Source: Diabetes Care - June 21, 2017 Category: Endocrinology Authors: Russell-Jones, D.; Bode, B. W.; De Block, C.; Franek, E.; Heller, S. R.; Mathieu, C.; Philis-Tsimikas, A.; Rose, L.; Woo, V. C.; Osterskov, A. B.; Graungaard, T.; Bergenstal, R. M. Tags: Emerging Technologies and Therapeutics Source Type: research
IGF1 and IGF2 specificities to the two insulin receptor isoforms are determined by insulin receptor amino acid 718
ConclusionMutating position 718 in human IR-B to the proline found at position 718 in human IR-A increased IGF1 and IGF2 affinity to a level comparable to IR-A and mutating position 718 in IR-A to the lysine found at position 718 in IR-B decreased IGF1 and IGF2 affinity to a level comparable to IR-B, whereas a negatively charged glutamate did not. These changes in the affinities were also reflected in the IR phosphorylation pattern, meaning that position 718 is important for both affinity and activation of the receptor. It should be emphasized that none of the mutations affected insulin affinity, indicating that the mutati...
Source: PLoS One - June 1, 2017 Category: Biomedical Science Authors: Mie Andersen Source Type: research
Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.
This article reviews pharmacokinetic (PK) and pharmacodynamic (PD) concepts relating to the pharmacology of basal insulin analogs. Understanding the pharmacology of currently available long-acting basal insulins and the techniques used to assess PK and PD parameters (e.g. the euglycemic clamp method) is important when considering the efficacy and safety of these agents, and can help in understanding the rationale for specific dosing strategies when tailoring therapy for a specific patient. Basal insulins such as insulin glargine 100 units (U)/mL and insulin detemir show improved PK/PD characteristics compared with the inte...
Source: Current Medical Research and Opinion - May 26, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research
The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.
CONCLUSION: The improved pharmacodynamic/pharmacokinetic profiles of new long-acting insulin formulations provide greater glycemic control with once-daily dosing. With the growing number of therapeutic choices available, physicians have more scope to individualize patient options for basal insulin therapy.
PMID: 28277867 [PubMed - as supplied by publisher] (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - March 10, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research
Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin detemir using continuous glucose monitoring: a randomized, cross-over, pilot study.
CONCLUSIONS: A CGM-based comparison demonstrated that once-daily IDeg showed fewer glycemic fluctuations than twice-daily IDet. IDeg appears to stabilize blood glucose levels better during both daytime and nighttime (particularly, before and after breakfast) with a lower insulin dosage.
PMID: 28234565 [PubMed - in process] (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - February 26, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Different insulin types and regimens for pregnant women with pre-existing diabetes.
CONCLUSIONS: With limited evidence and no meta-analyses, as each trial looked at a different comparison, no firm conclusions could be made about different insulin types and regimens in pregnant women with pre-existing type 1 or 2 diabetes. Further research is warranted to determine who has an increased risk of adverse pregnancy outcome. This would include larger trials, incorporating adequate randomisation and blinding, and key outcomes that include macrosomia, pregnancy loss, pre-eclampsia, caesarean section, fetal anomalies, and birth trauma.
PMID: 28156005 [PubMed - as supplied by publisher] (Source: Cochrane Da...
Source: Cochrane Database of Systematic Reviews - February 2, 2017 Category: Journals (General) Authors: O'Neill SM, Kenny LC, Khashan AS, West HM, Smyth RM, Kearney PM Tags: Cochrane Database Syst Rev Source Type: research
Economic outcomes with the conversion of insulin delivery methods in hospitals.
CONCLUSION: Switching RAI from IPS of 3-mL pens of insulin aspart to one-time unit dose insulin lispro dispensed from FS 3-mL vials as needed significantly reduced insulin wastage and associated acquisition costs at the 3 combined hospitals. Conversion of basal insulin from IPS of 3-mL pens of insulin detemir to CUD of 10-mL vials of insulin detemir was associated with a significant reduction in insulin wastage and associated acquisition costs at 3 hospitals combined.
PMID: 28133990 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 1, 2017 Category: Health Management Tags: J Med Econ Source Type: research
Insulin Detemir in Combination with Oral Antidiabetic Drugs Improves Glycemic Control in Persons with Type 2 Diabetes in Near East Countries: Results from the Lebanese Subgroup.
CONCLUSIONS: Initiating insulin detemir in a clinical health care setting among Lebanese with type 2 diabetes mellitus on OADs improves glycemic control with no increase in hypoglycemia, adverse events or weight compared with baseline.
PMID: 28115821 [PubMed - in process] (Source: Ethnicity and Disease)
Source: Ethnicity and Disease - January 26, 2017 Category: Global & Universal Tags: Ethn Dis Source Type: research
Design and rationale of a large, international, prospective cohort study to evaluate the occurrence of malformations and perinatal/neonatal death using insulin detemir in pregnant women with diabetes in comparison with other long-acting insulins
There are a lack of data regarding the effect of basal insulin analogues on rates of events like congenital malformation and perinatal mortality in diabetic pregnancy. (Source: BMC Pregnancy and Childbirth)
Source: BMC Pregnancy and Childbirth - January 18, 2017 Category: OBGYN Authors: Elisabeth R. Mathiesen, Henning Andersen, Sofia I. I. Kring and Peter Damm Source Type: research
Comparing effects of insulin analogues and human insulin on nocturnal glycaemia in hypoglycaemia ‐prone people with Type 1 diabetes
ConclusionsTreatment with insulin analogue reduces the occurrence of nocturnal hypoglycaemia assessed by nocturnal glucose profiles in people with Type 1 diabetes prone to severe hypoglycaemia. Nocturnal glucose profiles provide a more comprehensive assessment of clinical benefit of insulin regimens as compared to conventional recording of hypoglycaemia.This article is protected by copyright. All rights reserved. (Source: Diabetic Medicine)
Source: Diabetic Medicine - January 17, 2017 Category: Endocrinology Authors: P. L. Kristensen, L. Tarnow, C. Bay, K. N ørgaard, T. Jensen, H.‐H. Parving, H. Perrild, H. Beck‐Nielsen, J. S. Christiansen, B. Thorsteinsson, U. Pedersen‐Bjergaard Tags: Research Article Source Type: research
Insulin degludec is associated with less frequent and milder hypoglycemia in insulin-deficient patients with type 1 diabetes compared with insulin glargine or detemir
ConclusionPatients with unstable glycemic control under IGlar/IDet treatment did not improve glycemic control upon switching to IDeg, but the frequency and the degree of hypoglycemia was reduced in insulin-deficient outpatients with type 1 diabetes, especially in those suffering from severe hypoglycemia. (Source: Diabetology International)
Source: Diabetology International - January 17, 2017 Category: Endocrinology Source Type: research
Insulin aspart/insulin detemir
(Source: Reactions Weekly)
Source: Reactions Weekly - December 31, 2016 Category: Drugs & Pharmacology Source Type: research
A comparison of IDeg + IAsp versus IDet + IAsp in subjects with type 1 diabetes: subgroup analysis of Japanese subjects
ConclusionThe findings were consistent with those of the global trial population. IDeg + IAsp may represent an improvement on current standard treatments for Japanese patients with T1DM. (Source: Diabetology International)
Source: Diabetology International - November 30, 2016 Category: Endocrinology Source Type: research
Insulin detemir versus glyburide in women with gestational diabetes mellitus
. (Source: Gynecological Endocrinology)
Source: Gynecological Endocrinology - September 5, 2016 Category: Endocrinology Authors: Ronit Koren Eran Ashwal Moshe Hod Yoel Toledano Source Type: research
Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2 –16 Years
ConclusionAlthough treatment with IDet and IAsp is associated with development of specific and cross-reacting antibodies, no correlation between insulin antibodies and basal insulin dose or HbA1c was found.FundingNovo Nordisk A/S.ClinicalTrials.gov identifiers: NCT00435019 and NCT00623194. (Source: Diabetes Therapy)
Source: Diabetes Therapy - September 5, 2016 Category: Endocrinology Source Type: research
